H.C. Wainwright raised the firm’s price target on Dare Bioscience to $12 from $6 and keeps a Buy rating on the shares post the Q2 report. The analyst thinks Dare will need additional financing for the sildenafil cream program, though it thinks financing options will emerge as the regulatory pathway is settled. The target change reflects the 1-for-12 reverse stock split in June and the removal of Xaciato from the valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
- Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
- DARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Daré Bioscience Regains Nasdaq Compliance, Advances Phase 3 Trials
- Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule